Innovation in paediatric and adult congenital cardiology increasingly depends on collaboration among academia, industry, and professional communities. From this perspective, the author argues that clinical prediction represents a natural convergence point for these stakeholders, aligning safe, personalised care with economic incentives. The author discusses emerging evidence highlighting the promise of artificial intelligence-driven prediction across various cardiovascular domains, while highlighting current limitations related to narrow scope, static design, and weak integration into clinical decision-making. Medicine-based evidence and a high-quality, inclusive data infrastructure may help address these gaps. Together, these approaches, along with stakeholders upholding their responsibilities, define a path towards predictive innovation.